BAD HOMBURG, Germany, Jan. 9, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, will accelerate its share buyback program and start the repurchase of the second tranche. The program – presented during the company's Capital Markets Day on June 17, 2025 – has a total volume of EUR 1 billion. Under the second tranche, the company plans to repurchase its own shares for a total amount of around EUR 415 million from January ...

Core Insights - Fresenius Medical Care AG reported continued revenue growth in Q3 2025, achieving a Group organic growth of 10% and an operating income margin of 11.7%, indicating strong operational and financial progress [1][6][26]. Financial Performance - Q3 2025 revenue reached EUR 4,885 million, a 3% increase year-on-year, with an 8% increase at constant currency and a 10% organic growth [1][8]. - Operating income for Q3 2025 was EUR 477 million, up 3% year-on-year, while operating income excluding special items grew by 22% to EUR 574 million [14][19]. - Net income increased by 29% to EUR 275 million in Q3 2025, with net income excluding special items rising by 36% to EUR 322 million [20][19]. Segment Performance - Care Enablement saw a significant operating income growth of 38%, reaching a margin of 7.6% [1][18]. - Value-Based Care revenue grew by 34% to EUR 576 million, driven by an increase in member months due to contract expansion [11][19]. - Care Delivery revenue decreased by 2% to EUR 3,402 million, impacted by divestitures, but showed a positive organic growth of 6% [8][13]. Strategic Initiatives - The FME Reignite strategy is advancing, with the launch of a share buyback program and an increase in ownership of Interwell Health [1][7]. - The FME25+ transformation program delivered EUR 47 million in sustainable savings in Q3 2025, contributing to a total of EUR 174 million in savings for the first nine months [3][19]. Capital Allocation - An initial share buyback program of EUR 1.0 billion was announced, with EUR 151 million spent on repurchasing 3.6 million shares by September 30, 2025 [7][24]. - The net leverage ratio improved to 2.6x in Q3 2025, reflecting effective capital management alongside share buybacks and investments in Value-Based Care [24][6]. Outlook - The company confirmed its fiscal 2025 outlook, expecting positive revenue growth and operating income growth excluding special items in the high-teens to high-twenties percent range [26][27].